GE Healthcare will acquire PAA Laboratories, a developer and supplier of cell culture media for biopharmaceutical research and vaccine manufacturing. The acquisition expands GE Healthcare’s offering of products and services for cell biology research and the discovery and manufacture of biopharmaceuticals including recombinant proteins, antibodies and vaccines. Financial terms were not disclosed.

PAA Laboratories develops and manufactures specialized cell culture products such as media, sera, growth supplements and reagents for use in biomedical research and in the production of protein-based pharmaceuticals. The company has manufacturing facilities registered with the FDA, and recently implemented manufacturing facilities for powdered cell culture media to meet demand for these products from the biopharmaceutical industry.

“The acquisition of PAA Laboratories is a significant step forward for our Life Sciences business and for biopharmaceutical manufacturing globally,” said Kieran Murphy, president and chief executive officer of GE Healthcare Life Sciences. “We believe that an integrated approach, where we can help customers optimize every stage of their manufacturing process, has the potential to reduce cost of entry, deliver higher yields of finished product and reduce time to market.”

Rainer Burian, chief executive officer of PAA Laboratories said, “This is a great opportunity for the professional team of staff at PAA Laboratories and we are very excited to become part of GE Healthcare’s Life Sciences business. The Board of Directors of PAA Laboratories strongly believes that joining such a well-respected and recognized organization will give us significant opportunities to grow our business further with new technologies, products and services.”